The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 9: 1314 - 1319

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.09.023

Reviews

Advances in the study of immune checkpoint inhibitors⁃related colitis

  • Xiaona MENG ,
  • Xu SUN ,
  • Huaimin LIU
Expand
  • Department of Integrated Chinese and Western Medicine，the Affiliated Cancer Hospital of Zhengzhou University & He′nan Cancer Hospital，Zhengzhou 450008，China

Received date: 2024-01-09

  Online published: 2024-05-15

Fold

Abstract

Immune checkpoint inhibitors （ICIs）， including cytotoxic T?lymphocyte?associated protein 4 （CTLA?4） inhibitors and programmed cell death receptor 1 （PD?1） inhibitors and their ligand 1 （PD?L1） inhibitors， have transformed the clinical outcomes of many patients with malignancies. programmed cell death receptor 1 （PD?1） inhibitors and their ligand 1 （PD?L1） inhibitors have changed the clinical outcomes of many patients with malignancies and have become the most important anti?tumor tools available. With the widespread use of immunotherapy， immune?related adverse events （irAEs） induced by ICIs have gradually attracted clinical attention， among which ICI?related colitis has become the most common adverse event in the gastrointestinal system. In this paper， we describe the epidemiology， pathogenesis and clinical management of ICI?related colitis， with the aim of providing reference for clinicians to identify and treat ICI?related colitis in a timely manner.

Key words： immune checkpoint inhibitors; immune?related adverse events; colitis

Cite this article

Xiaona MENG , Xu SUN , Huaimin LIU . Advances in the study of immune checkpoint inhibitors⁃related colitis[J]. The Journal of Practical Medicine, 2024 , 40(9) : 1314 -1319 . DOI: 10.3969/j.issn.1006-5725.2024.09.023

References

1 ZHANG B， WU Q， ZHOU Y L， et al. Immune-related adverse events from combination immunotherapy in cancer patients： A comprehensive meta-analysis of randomized controlled trials ［J］. Inte Immunopharmacol， 2018， 63： 292-298. doi:10.1016/j.intimp.2018.08.014
2 PARENTE P， MAIORANO B A， CIARDIELLO D， et al. Clinic， Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity： Some News and Reappraisal from a Mono-Institutional Experience ［J］. Diagnostics （Basel， Switzerland）， 2022， 12（3）： 685-697. doi:10.3390/diagnostics12030685
3 LARKIN J， HODI F S， WOLCHOK J D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma ［J］. N Engl J Med， 2015， 373（13）： 1270-1271. doi:10.1056/nejmc1509660
4 RAMOS-CASALS M， BRAHMER J R， CALLAHAN M K， et al. Immune-related adverse events of checkpoint inhibitors ［J］. Nat Rev Dis Primers， 2020， 6（1）： 38-90. doi:10.1038/s41572-020-0160-6
5 SOULARUE E， LEPAGE P， COLOMBEL J F， et al. Enterocolitis due to immune checkpoint inhibitors： a systematic review ［J］. Gut， 2018， 67（11）： 2056-2067. doi:10.1136/gutjnl-2018-316948
6 WEBER J S， K?HLER K C， HAUSCHILD A. Management of immune-related adverse events and kinetics of response with ipilimumab ［J］. J Clin Oncol， 2012， 30（21）： 2691-2697. doi:10.1200/jco.2012.41.6750
7 ASCIERTO P A， DEL VECCHIO M， ROBERT C， et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma： a randomised， double-blind， multicentre， phase 3 trial ［J］. Lancet Oncol， 2017， 18（5）： 611-622. doi:10.1016/s1470-2045(17)30231-0
8 PAGAN A， ARROYO-MARTINEZ Y M， TANDON A， et al. Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis ［J］. Cureus， 2020， 12（6）： e8613-e8617.
9 KELLY-GOSS M R， BADRAN Y R， DOUGAN M. Update on Immune Checkpoint Inhibitor Enterocolitis ［J］. Curr Gastroenterol Rep， 2022， 24（12）： 171-181. doi:10.1007/s11894-022-00852-7
10 ABU-SBEIH H， FALECK D M， RICCIUTI B， et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease ［J］. J Clin Oncol， 2020， 38（6）： 576-583. doi:10.1200/jco.19.01674
11 WEINGARDEN A R， GUBATAN J， SINGH S， et al. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival ［J］. World J Gastroenterol， 2022， 28（39）： 5750-5763. doi:10.3748/wjg.v28.i39.5750
12 ROUTY B， GOPALAKRISHNAN V， DAILLèRE R， et al. The gut microbiota influences anticancer immunosurveillance and general health ［J］. Nat Rev Clin Oncol， 2018， 15（6）： 382- 396. doi:10.1038/s41571-018-0006-2
13 ABU-SBEIH H， HERRERA L N， TANG T， et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis ［J］. J Immunother Cancer， 2019， 7（1）： 242-253. doi:10.1186/s40425-019-0714-x
14 HASAN ALI O， BERNER F， BOMZE D， et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors ［J］. Eur J Cancer， 2019， 107： 8-14. doi:10.1016/j.ejca.2018.11.009
15 W?LFFER M， BATTKE F， SCHULZE M， et al. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma ［J］. Cancers（Basel）， 2022， 14（2）： 302-323. doi:10.3390/cancers14020302
16 OKIYAMA N， TANAKA R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors ［J］. Allergol Int， 2022， 71（2）： 169-178. doi:10.1016/j.alit.2022.01.001
17 ZHOU X， CHEN X， HAN L， et al. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy ［J］. Clin Sci， 2022， 136（10）： 771-785. doi:10.1042/cs20210042
18 MILLING L， ZHANG Y， IRVINE D J. Delivering safer immunotherapies for cancer ［J］. Adv Drug Deliv Rev， 2017， 114： 79-101. doi:10.1016/j.addr.2017.05.011
19 YANG H， YAO Z， ZHOU X， et al. Immune-related adverse events of checkpoint inhibitors： Insights into immunological dysregulation ［J］. Clin Immunol， 2020， 213： 108377-108387. doi:10.1016/j.clim.2020.108377
20 KUMAR P， SAINI S， PRABHAKAR B S. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis ［J］. Semin Cancer Biol， 2020， 64： 29-35. doi:10.1016/j.semcancer.2019.01.006
21 KUMAR P， BHATTACHARYA P， PRABHAKAR B S. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity ［J］. J Autoimmun， 2018， 95： 77-99. doi:10.1016/j.jaut.2018.08.007
22 LUOMA A M， SUO S， WILLIAMS H L， et al. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy ［J］. Cell， 2020， 182（3）： 655-671. doi:10.1016/j.cell.2020.06.001
23 BLASCHITZ C， RAFFATELLU M. Th17 cytokines and the gut mucosal barrier ［J］. J Clin Immunol， 2010， 30（2）： 196-203. doi:10.1007/s10875-010-9368-7
24 WESTDORP H， SWEEP M W D， GORRIS M A J， et al. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis ［J］. Front Immunol， 2021， 12： 768957. doi:10.3389/fimmu.2021.768957
25 AL-QADAMI G， VAN SEBILLE Y， LE H， et al. Gut microbiota： implications for radiotherapy response and radiotherapy-induced mucositis ［J］. Expert Rev Gastroenterol Hepatol， 2019， 13（5）： 485-496. doi:10.1080/17474124.2019.1595586
26 SUN S， LUO L， LIANG W， et al. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade ［J］. Pro Nat Acad Sci U S A， 2020， 117（44）： 27509-27515. doi:10.1073/pnas.1921223117
27 CHAPUT N， LEPAGE P， COUTZAC C， et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab ［J］. Ann Oncol， 2017， 28（6）： 1368-1379. doi:10.1093/annonc/mdx108
28 TAO R， DE ZOETEN E F， OZKAYNAK E， et al. Deacetylase inhibition promotes the generation and function of regulatory T cells ［J］. Nat Med， 2007， 13（11）： 1299-1307. doi:10.1038/nm1652
29 RENGA G， NUNZI E， PARIANO M， et al. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite ［J］. J Immunother Cancer， 2022， 10（3）： e003725. doi:10.1136/jitc-2021-003725
30 FRIEDMAN C F， PROVERBS-SINGH T A， POSTOW M A. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors： A Review ［J］. JAMA Oncol， 2016， 2（10）： 1346-1353. doi:10.1001/jamaoncol.2016.1051
31 DEPUTY M， DEVANABOINA R， BAKIR I AL， et al. The role of faecal calprotectin in the diagnosis of inflammatory bowel disease ［J］. BMJ， 2023， 380： e068947. doi:10.1136/bmj-2021-068947
32 ZOU F， WANG X， GLITZA OLIVA I C， et al. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis ［J］. J Immunother Cancer， 2021， 9（1）： e002058. doi:10.1136/jitc-2020-002058
33 NISHIDA T， IIJIMA H， ADACHI S. Immune checkpoint inhibitor-induced diarrhea/colitis： Endoscopic and pathologic findings ［J］. World J Gastrointest Pathophysiol， 2019， 10（2）： 17-28. doi:10.4291/wjgp.v10.i2.17
34 WANG Y， ABU-SBEIH H， MAO E， et al. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis ［J］. Inflamm Bowel Dis， 2018， 24（8）： 1695-1705. doi:10.1093/ibd/izy104
35 DOUGAN M， WANG Y， RUBIO-TAPIA A， et al. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis： Expert Review ［J］. Gastroenterology， 2021， 160（4）： 1384-1393. doi:10.1053/j.gastro.2020.08.063
36 HUGHES M S， MOLINA G E， CHEN S T， et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors ［J］. J Immunother Cancer， 2019， 7（1）： 292-302. doi:10.1186/s40425-019-0756-0
37 GARCIA-NEUER M， MARMARELIS M E， JANGI S R， et al. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients ［J］. Cancer Immunol Res， 2017， 5（4）： 286-291. doi:10.1158/2326-6066.cir-16-0302
38 Common terminology criteria for adverse events （Ctcae V 5.0） ［EB/OL］.
39 BADRAN Y R， SHIH A， LEET D， et al. Immune checkpoint inhibitor-associated celiac disease ［J］. J Immunother Cancer， 2020， 8（1）： e00958. doi:10.1136/jitc-2020-000958
40 SINGH B P， MARSHALL J L， HE A R. Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors ［J］. Oncologist， 2020， 25（3）： 197-202. doi:10.1634/theoncologist.2018-0304
41 KIPARIZOSKA S， MURPHY M E， MATTAR M C. Check this out： treatment paradigms in immune-checkpoint inhibitor colitis ［J］. Curr Opin Gastroenterol， 2023， 39（1）： 43-49. doi:10.1097/mog.0000000000000892
42 NICOLAIDES S， BOUSSIOUTAS A. Immune-Related Adverse Events of the Gastrointestinal System ［J］. Cancers（Basel）， 2023， 15（3）： 691-703. doi:10.3390/cancers15030691
43 BADRAN Y R， COHEN J V， BRASTIANOS P K， et al. Concurrent therapy with immune checkpoint inhibitors and TNF-α blockade in patients with gastrointestinal immune-related adverse events ［J］. J Immunother Cancer， 2019， 7（1）： 226-237. doi:10.1186/s40425-019-0711-0
44 ZOU F， FALECK D， THOMAS A， et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer： a two-center observational study ［J］. J Immunother Cancer， 2021， 9（11）： e003277. doi:10.1136/jitc-2021-003277
45 DORA D， BOKHARI S M Z， ALOSS K， et al. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events： Emergence of Novel Biomarkers for Cancer Immunotherapy ［J］. Int J Mol Sci， 2023， 24（3）： 2769-2795. doi:10.3390/ijms24032769
46 MU A， MCDONALD D， JARMUSCH A K， et al. Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection ［J］. Microbiome， 2021， 9（1）： 92-100. doi:10.1186/s40168-021-01026-9
Options
Outlines

/

〈 〉